Analyst Estimates
| YR Ending | Q1 Mar | Q2 Jun | Q3 Sep | Q4 Dec | FISC YR Annual | NUM Brokers (FISC) | CAL YR Annual | NUM Brokers (CAL) | | 2022 | 0 | 0 | 0 | 0 | 6.91 | 7 | 6.91 | 7 | | 2021 | 0 | 0 | 0 | 0 | 5.29 | 8 | 5.29 | 8 | | 2020 | 0 | 0 | 0 | 0 | 3.69 | 12 | 3.69 | 12 | | 2019 | 0.18 | 0.29 | 0.39 | 0.6 | 1.65 | 16 | 1.65 | 16 | | 2018 | -0.47A | -0.07A | 0.52A | 0.14 | 0.16 | 12 | 0.16 | 12 | | 2017 | -0.9A | -0.68A | -0.13A | 0.07A | -1.62 | 13 | -1.62 | 13 | | 2016 | -0.22A | -0.46A | -0.43A | -0.51A | -1.63 | 12 | -1.63 | 12 | | 2015 | -0.01A | -0.28A | -0.4A | -0.34A | -1.05 | 7 | -1.05 | 7 | | 2014 | -0.17A | -0.18A | -0.21A | -0.26A | -0.81 | 6 | -0.81 | 6 | | 2013 | -0.18A | -0.18A | -0.17A | -0.16A | -0.69 | 9 | -0.69 | 9 | | 2012 | -0.01A | -0.01A | -0.05A | 0.14A | 0.08 | 8 | 0.08 | 8 |
|
 |
Disclaimer: Mean Earnings Estimates are calculated by First Call based on the earnings projections made by the analysts who cover Neurocrine Biosciences. Please note that any opinions, estimates or forecasts regarding Neurocrine Biosciences performance made by these analysts (and therefore the Mean estimate numbers) are theirs alone and do not represent opinions, forecasts or predictions of Neurocrine Biosciences or its management. Neurocrine Biosciences does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
